Tango Therapeutics (TNGX) FCF Margin (2020 - 2025)
Tango Therapeutics' (TNGX) quarterly FCF Margin came in at 57.36% in Q3 2025, up 22558.0% year-on-year from N/an in Q3 2024, and up 95.04% quarter-over-quarter from 1156.05% in Q2 2025.
Tango Therapeutics (TNGX) FCF Margin (2020 - 2025) Analysis & Trends
Tango Therapeutics' FCF Margin history runs 6 years deep, the most recent figure standing at 57.36% for Q3 2025.
- On a quarterly basis, FCF Margin rose 22558.0% year-over-year to 57.36% in Q3 2025; TTM through Mar 2026 was 248.78%, a 8344.0% increase from a year earlier, with the FY2025 full-year figure at 223.11%, up 9127.0% from the prior year.
- FCF Margin rose to 57.36% in Q3 2025 per TNGX's latest filing, from 1156.05% in the prior quarter.
- Across five years, FCF Margin topped out at 40.43% in Q2 2021 and bottomed at 1156.05% in Q2 2025.
- The 5-year median for FCF Margin is 379.62% (2022), against an average of 432.4%.
- Across the five-year window, FCF Margin jumped 36549 bps in 2023 and plunged 103451 bps in 2025, its largest moves.
- Year by year, FCF Margin stood at 291.1% in 2021, then sank by 57 bps to 457.14% in 2022, then dropped by 6 bps to 482.51% in 2023, then sank by 88 bps to 909.28% in 2024, then soared by 94 bps to 57.36% in 2025.
- Per Business Quant, the three latest TNGX FCF Margin figures stand at 57.36% (Q3 2025), 1156.05% (Q2 2025), and 774.26% (Q1 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Tango Therapeutics | 3.94 Bn | 3.78 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -57.36% |
| Jun 30, 2025 | -1,156.05% |
| Mar 31, 2025 | -774.26% |
| Dec 31, 2024 | -909.28% |
| Sep 30, 2024 | -282.94% |
| Jun 30, 2024 | -121.54% |
| Mar 31, 2024 | -584.48% |
| Dec 31, 2023 | -482.51% |
| Sep 30, 2023 | -290.26% |
| Jun 30, 2023 | -172.19% |
| Mar 31, 2023 | -616.15% |
| Dec 31, 2022 | -457.14% |
| Sep 30, 2022 | -379.62% |
| Jun 30, 2022 | -537.69% |
| Mar 31, 2022 | -523.88% |
| Dec 31, 2021 | -291.10% |
| Sep 30, 2021 | -323.03% |
| Jun 30, 2021 | -40.43% |
| Mar 31, 2021 | -215.75% |
| Dec 31, 2020 | -23.12% |